Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission
Results from the Iceberg study
Dados Bibliográficos
| ID | 15519281 |
|---|---|
| Autores | Albino J Oliveira-Maia (0000-0001-5071-3007, Champalimaud Foundation), Benoît Rive (Janssen (France), autor correspondente), Yordan Godinov, Siobhán Mulhern-Haughey (0000-0002-9708-4356, Janssen (Ireland)) |
| Ano | 2024 |
| Volume | 15 |
| Páginas | 1459633-1459633 |
| Data de publicação | 2024-10-07 |
| Peer Reviewed | Sim |
| Open Access | Sim |
| Tipo | ARTICLE |
| Periódico | Frontiers in Psychiatry (JOURNAL) |
| Identificadores do periódico | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Editora | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2024.1459633 |
| PMID | 39435126 |
| OpenAlex | W4403199683 |
| Idioma | EN |
| Referências citadas | 4 |
For patients with TRD, esketamine NS had a significant functional benefit versus RWT after 6 months of treatment. Irrespective of treatment, achievement of clinical response or remission was insufficient to attain functional remission. Nevertheless, clinical remission increased the likelihood of achieving functional remission, further supporting an important role for clinical remission in for the path towards functional recovery
Anesthesia · Iceberg · Nasal administration · Nasal spray · Ginkgo biloba and Cashew Applications · Medicine · Olfactory and Sensory Function Studies · Treatment of Major Depression · Geology · Pharmacology
| Velocidade de citação | historical |
|---|---|
| Altamente citado | Não |